Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors.
Sanofi acquiring Ablynx
Latest NewsBriefly after Belgian nanobody maker Ablynx rejected a €2.3bn take-over bid of Novo, its board accepted a €3.9bn tender of its R&D partner Sanofi. It’s the second large take-over of Sanofi this month.
EMA recommends seven new drugs for market
Latest NewsThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) greenlighted seven medicines for approval at its January 2018 meeting, including one orphan medicine, and one biosimilar.
Congenica Appoints New CEO
AppointmentsCongenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors.
New wave of optimism for European biotech stocks
BackgroundThe European biotech stock market witnessed an increase in IPO and follow-on financing volumes in 2017. According to the new BIOCOM capital market report, published in November during BIO-Europe in Berlin, more than half the money was raised on the US Nasdaq. Within Europe, Euronext is still is the most attractive location – but Stockholm is catching up.
Bacterium blocks dengue and Zika virus transmission
Latest NewsScientists at the University of Glasgow have found a bacterial strain which blocks dengue and Zika virus transmission from mosquitoes.
Novartis in US$170m licence deal with Spark Therapeutics
Latest NewsNovartis AG has strengthened its ophtalmology portfolio by acquiring a licence for Spark Therapeutics’ voretigene neparvovec (Luxturna), an FDA-approved gene therapy that corrects mutations in RPE65, which leads to juvenile blindness in homozygotous carriers.
Connectivity is the future
OpinionPharmaPack 2018:?The promises of digitalised medicine don’t stop at injection pens or autoinjectors. One of the early adopters in the field is Swiss Haselmeier AG (Pharmapack: hall 7.1, booth L19). European Biotechnology spoke with Paul E. Jansen, Member of the Board, from Haselmeier’s Boston office about how connected devices could define a new paradigm in therapy compliance and control of chronic diseases, and how they will shape the market.
Emil Billbäck appointed CEO of BONESUPPORT
AppointmentsBONESUPPORT (Nasdaq Stockholm: BONEX) announces that the Board of Directors has appointed Emil Billbäck as the new CEO of BONESUPPORT HOLDING AB. Mr. Billbäck has over 20 years management experience from the life science industry and the Board of Directors is of the opinion that he has the ideal profile to implement the Company’s strategy and to deliver shareholder value. He will join BONESUPPPORT on 1st March 2018 when he will replace Richard Davies who has been the Company’s CEO since January 2016.
Protein keeps breast cancer metastases at bay
Latest NewsSpanish researchers have identified a protein that keeps breast cancer stem cell in a dormant state preventing them from forming metastases. A German team found an endothelial receptor protein that prevents dormant micrometastases in the blood to invade tissue.
Seventure Partners joins US$35m round into Zipongo
Latest NewsVenture capital firm Seventure Partners has joined a US$35m Series B Round in Digital Nutrition Platform Zipongo. The US$9m invested into the Californian company comes from Seventures’ €160m Health for Life Capital fund, the premier fund dedicated to the expanding microbiome and nutrition space.